237 related articles for article (PubMed ID: 2349963)
21. [Sensibility and specificity of N-myc oncogene with respect to other prognostic factors in 15 neuroblastomas].
Queizán A; García-Miguel P; Belló MJ; Castresana JC; Rey JA; Pestaña A
Cir Pediatr; 1995 Jul; 8(3):96-8. PubMed ID: 8527322
[TBL] [Abstract][Full Text] [Related]
22. Proliferation marker KI-S5 discriminates between favorable and adverse prognosis in advanced stages of neuroblastoma with and without MYCN amplification.
Krams M; Hero B; Berthold F; Parwaresch R; Harms D; Rudolph P
Cancer; 2002 Feb; 94(3):854-61. PubMed ID: 11857322
[TBL] [Abstract][Full Text] [Related]
23. Prolonged N-myc protein half-life in a neuroblastoma cell line lacking N-myc amplification.
Cohn SL; Salwen H; Quasney MW; Ikegaki N; Cowan JM; Herst CV; Kennett RH; Rosen ST; DiGiuseppe JA; Brodeur GM
Oncogene; 1990 Dec; 5(12):1821-7. PubMed ID: 2284101
[TBL] [Abstract][Full Text] [Related]
24. Preferential amplification of the paternal allele in neuroblastomas with N-myc amplification.
Cheng JM; Hiemstra JL; Schneider SS; Kaufman BA; Naumova A; Cheung NK; Cohn SL; Diller L; Sapienza C; Brodeur GM
Prog Clin Biol Res; 1994; 385():43-9. PubMed ID: 7972236
[TBL] [Abstract][Full Text] [Related]
25. Combined analysis of DNA ploidy index and N-myc genomic content in neuroblastoma.
Bourhis J; Bénard J; DeVathaire F; Wilson GD; Hartmann O; Terrier-Lacombe MJ; Boccon-Gibod L; Lemerle J; Riou G
Prog Clin Biol Res; 1991; 366():107-13. PubMed ID: 2068130
[No Abstract] [Full Text] [Related]
26. Analysis of the prognostic factors relating to better clinical outcome in ganglioneuroblastoma.
Kubota M; Suita S; Tajiri T; Shono K; Fujii Y
J Pediatr Surg; 2000 Jan; 35(1):92-5. PubMed ID: 10646782
[TBL] [Abstract][Full Text] [Related]
27. A neuroblastoma cell line derived from a case detected through a mass screening system in Japan: a case report including the biologic and phenotypic characteristics of the cell line.
Hiraiwa H; Hamazaki M; Takata A; Kikuchi H; Hata J
Cancer; 1997 May; 79(10):2036-44. PubMed ID: 9149033
[TBL] [Abstract][Full Text] [Related]
28. Trk mRNA and low affinity nerve growth factor receptor mRNA expression and triploid DNA content in favorable neuroblastoma tumors.
Kogner P; Barbany G; Björk O; Castello MA; Donfrancesco A; Falkmer UG; Hedborg F; Kouvidou H; Persson H; Raschella G
Prog Clin Biol Res; 1994; 385():137-45. PubMed ID: 7972205
[TBL] [Abstract][Full Text] [Related]
29. The use of fine-needle aspiration cytology in the molecular characterization of neuroblastoma in children.
Fröstad B; Martinsson T; Tani E; Falkmer U; Darnfors C; Skoog L; Kogner P
Cancer; 1999 Apr; 87(2):60-8. PubMed ID: 10227595
[TBL] [Abstract][Full Text] [Related]
30. Determination of N-myc gene amplification in neuroblastoma by differential polymerase chain reaction.
Gilbert J; Norris MD; Haber M; Kavallaris M; Marshall GM; Stewart BW
Mol Cell Probes; 1993 Jun; 7(3):227-34. PubMed ID: 8366868
[TBL] [Abstract][Full Text] [Related]
31. Detection of N-myc oncogene expression in human neuroblastoma by in situ hybridization and blot analysis: relationship to clinical outcome.
Grady-Leopardi EF; Schwab M; Ablin AR; Rosenau W
Cancer Res; 1986 Jun; 46(6):3196-9. PubMed ID: 2421891
[TBL] [Abstract][Full Text] [Related]
32. Expression of N-myc and c-src protooncogenes correlating to the undifferentiated phenotype and prognosis of primary neuroblastomas.
Matsunaga T; Takahashi H; Ohnuma N; Tanabe M; Yoshida H; Iwai J; Shirasawa H; Simizu B
Cancer Res; 1991 Jun; 51(12):3148-52. PubMed ID: 2039993
[TBL] [Abstract][Full Text] [Related]
33. N-myc amplification in neuroblastomas: histopathological, DNA ploidy, and clinical variables.
Oppedal BR; Oien O; Jahnsen T; Brandtzaeg P
J Clin Pathol; 1989 Nov; 42(11):1148-52. PubMed ID: 2584426
[TBL] [Abstract][Full Text] [Related]
34. Detection of N-myc gene amplification in bone marrow specimen of stage IV neuroblastoma patients.
Brack T; Scholz RB; Milde-Langosch K; Heinsohn S; Löning T; Kabisch H
Cancer Detect Prev; 1992; 16(3):185-92. PubMed ID: 1458508
[TBL] [Abstract][Full Text] [Related]
35. Improved survival for patients with advanced neuroblastoma after high-dose combined chemotherapy based in part on N-myc amplification.
Suita S; Tajiri T; Sera Y; Takamatsu H; Mizote H; Nagasaki A; Kurosaki N; Hara T; Okamura J; Miyazaki S; Sugimoto T; Kawakami K; Eguchi H; Tsuneyoshi M
J Pediatr Surg; 2000 Dec; 35(12):1737-41. PubMed ID: 11101726
[TBL] [Abstract][Full Text] [Related]
36. Amplification of N-myc sequences in primary human neuroblastomas: correlation with advanced disease stage.
Brodeur GM; Seeger RC; Schwab M; Varmus HE; Bishop JM
Prog Clin Biol Res; 1985; 175():105-13. PubMed ID: 3991726
[No Abstract] [Full Text] [Related]
37. Amplification and rearrangement of DNA sequences from the chromosomal region 2p24 in human neuroblastomas.
Shiloh Y; Korf B; Kohl NE; Sakai K; Brodeur GM; Harris P; Kanda N; Seeger RC; Alt F; Latt SA
Cancer Res; 1986 Oct; 46(10):5297-301. PubMed ID: 3756879
[TBL] [Abstract][Full Text] [Related]
38. Evidence for nm23 RNA overexpression, DNA amplification and mutation in aggressive childhood neuroblastomas.
Leone A; Seeger RC; Hong CM; Hu YY; Arboleda MJ; Brodeur GM; Stram D; Slamon DJ; Steeg PS
Oncogene; 1993 Apr; 8(4):855-65. PubMed ID: 8384356
[TBL] [Abstract][Full Text] [Related]
39. N-myc amplification and neuronal differentiation in human primitive neuroectodermal tumors of the central nervous system.
Rouah E; Wilson DR; Armstrong DL; Darlington GJ
Cancer Res; 1989 Apr; 49(7):1797-801. PubMed ID: 2924321
[TBL] [Abstract][Full Text] [Related]
40. Unfavorable DNA ploidy and Ha-ras p21 findings in neuroblastomas detected through mass screening.
Kusafuka T; Nagahara N; Oue T; Imura K; Nakamura T; Kobayashi Y; Komoto Y; Fukuzawa M; Okada A; Nakayama M
Cancer; 1995 Aug; 76(4):695-9. PubMed ID: 8625168
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
